Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc S Raab

Showing results (41-50 of 177) with videos related to

Pageof 18
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2013
Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor loadKai Neben, Anna Jauch, Thomas Hielscher, et al.
Cancer|April 12, 2013
Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patientsLeopold Sellner, Christiane Heiss, Axel Benner, et al.
BMC Cancer|November 22, 2023
Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trialsJoseph Kauer, Emma P Freundt, Anita Schmitt, et al.
Leukemia|November 13, 2019
Cytogenetic subclone formation and evolution in progressive smoldering multiple myelomaMaximilian Merz, Thomas Hielscher, David Schult, et al.
Blood Cancer Journal|October 14, 2024
Patterns of progression in a contemporary cohort of 447 patients with smoldering multiple myelomaAnnika Werly, Mareike Hampel, Thomas Hielscher, et al.
Blood|October 7, 2006
Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl)Klaus Podar, Marc S Raab, Jing Zhang, et al.
British Journal of Haematology|July 14, 2016
Multiple myeloma: patient outcomes in real-world practiceKwee Yong, Michel Delforge, Christoph Driessen, et al.
Genes, Chromosomes & Cancer|January 15, 2010
NPM1 is overexpressed in hyperdiploid multiple myeloma due to a gain of chromosome 5 but is not delocalized to the cytoplasmNiels Weinhold, Jerome Moreaux, Marc S Raab, et al.
British Journal of Haematology|June 14, 2016
Multiple myeloma: practice patterns across EuropeMarc S Raab, Michele Cavo, Michel Delforge, et al.
Blood Advances|March 20, 2026
Telomere length and clonal hematopoiesis interact to influence outcomes in hematopoietic stem cell transplantationJake Tobin, Patrick Stelmach, Sarah Richter, et al.
Pageof 18

Showing results (41-50 of 177) with videos related to

Sort By:
Pageof 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2013
Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor loadKai Neben, Anna Jauch, Thomas Hielscher, et al.
Cancer|April 12, 2013
Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patientsLeopold Sellner, Christiane Heiss, Axel Benner, et al.
BMC Cancer|November 22, 2023
Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trialsJoseph Kauer, Emma P Freundt, Anita Schmitt, et al.
Leukemia|November 13, 2019
Cytogenetic subclone formation and evolution in progressive smoldering multiple myelomaMaximilian Merz, Thomas Hielscher, David Schult, et al.
Blood Cancer Journal|October 14, 2024
Patterns of progression in a contemporary cohort of 447 patients with smoldering multiple myelomaAnnika Werly, Mareike Hampel, Thomas Hielscher, et al.
Blood|October 7, 2006
Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl)Klaus Podar, Marc S Raab, Jing Zhang, et al.
British Journal of Haematology|July 14, 2016
Multiple myeloma: patient outcomes in real-world practiceKwee Yong, Michel Delforge, Christoph Driessen, et al.
Genes, Chromosomes & Cancer|January 15, 2010
NPM1 is overexpressed in hyperdiploid multiple myeloma due to a gain of chromosome 5 but is not delocalized to the cytoplasmNiels Weinhold, Jerome Moreaux, Marc S Raab, et al.
British Journal of Haematology|June 14, 2016
Multiple myeloma: practice patterns across EuropeMarc S Raab, Michele Cavo, Michel Delforge, et al.
Blood Advances|March 20, 2026
Telomere length and clonal hematopoiesis interact to influence outcomes in hematopoietic stem cell transplantationJake Tobin, Patrick Stelmach, Sarah Richter, et al.
Pageof 18